T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease
UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.
